Trial Profile
A Randomized Phase 2 Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors ArQule
- 23 Feb 2010 New trial record